Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04081389
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:39:35.469834+00:00
Published At
2023-09-11T00:00:00+00:00
Record Updated At
2023-09-11
Results Posted At
2023-09-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Early-Stage Breast Carcinoma", "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Prognostic Stage 0 Breast Cancer AJCC v8", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Triple-Negative Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-09-11"
protocolSection.identificationModule.nctId
"NCT04081389"
protocolSection.identificationModule.officialTitle
"Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-09-11"

Study condition terms

  • Anatomic Stage 0 Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Anatomic Stage I Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Anatomic Stage IA Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Anatomic Stage IB Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Anatomic Stage II Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Anatomic Stage IIA Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Anatomic Stage IIB Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Early-Stage Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor Negative (protocolSection.conditionsModule.conditions)
  • HER2/Neu Negative (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor Negative (protocolSection.conditionsModule.conditions)
  • Prognostic Stage 0 Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Prognostic Stage I Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Prognostic Stage IA Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Prognostic Stage IB Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Prognostic Stage II Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Prognostic Stage IIA Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Prognostic Stage IIB Breast Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Triple-Negative Breast Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.